BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Pancreatic cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for pancreatic cancer: 408 (275 sponsors; 55 newly posted in the last 180 days, 18 stopped in the last 180 days; 30 new-entrant sponsors). Momentum score 10, rank 70 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 9, Phase 1 133, Phase 2 170, Phase 3 46, Phase 4 1, N/A 49.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Revolution Medicines, Inc. RVMD11P2 3, P3 5, P1 322
Jiangsu HengRui Medicine Co., Ltd.4P2 1, P3 311
Exelixis EXEL3P3 2, P1 111
ITM Solucin GmbH2P3 200
Jiangxi Kvvit Pharmaceutical Co., Ltd. new entrant2P3 220
Astellas Pharma Global Development, Inc.7P1 3, P3 1, P2 302
Bristol-Myers Squibb BMY7P3 1, P2 4, P1 210
Akeso5P1 1, P2 3, P3 102
Incyte Corporation INCY4P3 1, P1 2, P2 102
Pfizer PFE4P1 3, P3 110
Evopoint Biosciences Inc.3P3 1, P2 1, P1 121
Genfleet Therapeutics (Shanghai) Inc.3P2 2, P3 120
Shanghai Hengrui Pharmaceutical Co., Ltd.3P2 1, P1 1, P3 121
Angiodynamics, Inc. ANGO2NA 1, P3 100
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2P3 1, P2 100
Immuneering Corporation IMRX2P2 1, P3 100
Innovent Biologics (Suzhou) Co. Ltd.2P2 1, P3 100
Qilu Pharmaceutical Co., Ltd.2P3 1, P1 100
RayzeBio, Inc.2P1 1, P3 102
Arcus Biosciences, Inc. RCUS1P3 100
Crinetics Pharmaceuticals Inc.1P3 100
CSPC Ouyi Pharmaceutical Co., Ltd.1P3 100
Eleison Pharmaceuticals LLC.1P3 100
ElmediX new entrant1P3 110
FutureGen Biopharmaceutical (Beijing) Co., Ltd1P3 100

New-entrant sponsors: Jiangxi Kvvit Pharmaceutical Co., Ltd., ElmediX.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2BeyondBio Inc.NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerLocally Advanced or Metastatic Pancreatic Cancerrecruiting75
2026-11-30 est.P2Ranok Therapeutics (Hangzhou) Co., Ltd.NCT07303465 To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC)recruiting60
2026-12 est.P2SynerGene Therapeutics, Inc.NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerMetastatic Pancreatic Canceractive not recruiting28
2026-12 est.P3GC Cell CorporationNCT04969731 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic CancerPancreatic Ductal Adenocarcinomarecruiting408
2026-12 est.P1/P2A2 Biotherapeutics Inc.NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionSolid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Smallactive not recruiting160
2026-12 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ducnot yet recruiting300
2026-12-15 est.P2EXACT Therapeutics ASNCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic CancerLocally Advanced Pancreatic Adenocarcinomarecruiting25
2026-12-25 est.P3Jiangsu Healthy Life Innovation Medical Technology Co., LtdNCT05653453 Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic CancerLocally Advanced Pancreatic Cancerrecruiting512
2026-12-30 est.P1/P2AkesoNCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerMetastatic Pancreatic Ductal Adenocarcinomaactive not recruiting110
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-31 est.P2Partner Therapeutics, Inc.NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Factive not recruiting250
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Allist Pharmaceuticals, Inc.NCT06008288 A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.KRAS P.G12C; Pancreatic Cancer; Solid Tumorrecruiting88
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2026-12-31 est.P1/P2Evopoint Biosciences Inc.NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsAdvanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancersrecruiting350
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-02 est.P1/P2Lumicell, Inc.NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersColorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Canceractive not recruiting66
2027-02 est.P1/P2GI Innovation, Inc.NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNSrecruiting102
2027-02-01 est.P1/P2Amplia Therapeutics LimitedNCT05355298 ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic CancerPancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinomaactive not recruiting62
2027-02-14 est.P1/P2Beijing BiotechNCT07480928 Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Diseaserecruiting42

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsPancreatic Neoplasmsrecruiting80
2026-10-31 est.P2Astellas Pharma Global Development, Inc.NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinomaactive not recruiting393
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-08-31 est.P1/P2Verastem, Inc. VSTMNCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerKRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplaactive not recruiting40
2026-08-29 est.P2/P3Panbela Therapeutics, Inc.NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IVrecruiting600
2026-08 est.P2Cornerstone Pharmaceuticals CLMNCT06518538 Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic CancerPancreatic Cancer Stage IVwithdrawn
2026-08 est.P1/P2AtlasMedx, IncorporatedNCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced MalignanciesAdvanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Prorecruiting122
2026-07-28 est.P1/P2Lantern Pharma Inc. LTRNNCT05933265 Study of LP-184 in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancactive not recruiting64
2026-07-15 est.P2Can-Fite BioPharma CANFNCT06387342 Namodenoson Treatment of Advanced Pancreatic CancerPancreatic Adenocarcinoma; Pancreatic Cancerrecruiting20
2026-07 est.P1/P2Prestige Biopharma Limited PBHNCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic CancerPancreatic Canceractive not recruiting80
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06-01 est.P2/P3Oncotelic Inc. OTLCNCT06079346 A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic CancerPancreatic Ductal Adenocarcinomarecruiting455
2026-06-01 est.P1/P2Alligator Bioscience ABNCT04888312 Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer PatientsMetastatic Pancreatic Ductal Adenocarcinomaactive not recruiting94
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500
2026-06 est.P1/P2CG Pharmaceuticals, IncNCT05249101 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinomaactive not recruiting70
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "pancreatic cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.